Results 1 to 10 of about 1,641 (192)

In Vitro Activity of Delafloxacin Against Corynebacterium spp. [PDF]

Antibiotics
Background/Objectives: The susceptibility of Corynebacterium spp. to antimicrobial agents is species-related, with increasing levels of resistance to fluoroquinolones in several species related to their continued use in clinical practice.
Montserrat Muñoz-Rosa, Cristina Elías-López, Rosa Pedraza, Cristina Riazzo, Cristina Arjona-Torres, Isabel Machuca, Rocio Tejero-García, Julian Torre-Cisneros, Luis Martínez-Martínez   +8 more
doaj   +4 more sources

Disproportionality Analysis of Fluoroquinolone‐Associated Peripheral Neuropathy in the FAERS Database (2007–2024) [PDF]

Clinical and Translational Science
Fluoroquinolones (FQs) are among the most frequently prescribed antibiotic classes worldwide. Despite their therapeutic versatility in treating bacterial infections, regulatory authorities recognized risks of persistent and potentially irreversible ...
Nimra Shamim, Kelly Doughty, Hau‐Tak Chau, James Brown, Robert Baldock, Ngan Pan Bennett Au   +5 more
doaj   +3 more sources

Variable In Vitro Efficacy of Delafloxacin on Multidrug-Resistant Pseudomonas aeruginosa and the Detection of Delafloxacin Resistance Determinants [PDF]

Antibiotics
Background: In this study, molecular mechanisms contributing to delafloxacin resistance in Pseudomonas aeruginosa strains were investigated. Delafloxacin is a recently approved fluoroquinolone currently introduced to clinical applications.
András Kubicskó, Katalin Kamotsay, Péter Banczerowski, László Sipos, Dóra Szabó, Béla Kocsis   +5 more
doaj   +3 more sources

Analysis of molecular mechanisms of delafloxacin resistance in Escherichia coli [PDF]

Scientific Reports
In this study delafloxacin resistance mechanisms in Escherichia coli strains were analyzed. Delafloxacin is a new fluoroquinolone, that is approved for clinical application however, resistance against this agent is scarcely reported.
András Kubicskó, Katalin Kamotsay, Dóra Szabó, Béla Kocsis   +3 more
doaj   +4 more sources

Structural basis of topoisomerase targeting by delafloxacin [PDF]

Nature Communications
Delafloxacin is a potent anionic fluoroquinolone approved for the treatment of respiratory infections that acts by trapping the DNA cleavage complexes of bacterial topoisomerase IV and gyrase.
Shabir Najmudin, Xiao-Su Pan, Beijia Wang, Lata Govada, Naomi E. Chayen, Noelia Rubio, Milo S. P. Shaffer, Henry S. Rzepa, L. Mark Fisher, Mark R. Sanderson   +9 more
doaj   +3 more sources

Detection of Delafloxacin Resistance Mechanisms in Multidrug-Resistant Klebsiella pneumoniae [PDF]

Antibiotics
Background: In this study, the mechanisms implicated in delafloxacin resistance in Klebsiella pneumoniae strains were investigated. Delafloxacin is a novel, broad-spectrum fluoroquinolone that has been approved for clinical application.
András Kubicskó, János Juhász, Katalin Kamotsay, Dora Szabo, Béla Kocsis   +4 more
doaj   +3 more sources

Effect of pH on antimicrobial activity of delafloxacin against Escherichia coli isogenic strains carrying diverse chromosomal and plasmid-mediated fluoroquinolone resistance mechanisms [PDF]

Microbiology Spectrum
The aim of this study is to evaluate the pH-dependent antimicrobial activities of delafloxacin against isogenic Escherichia coli strains carrying diverse fluoroquinolone resistance mechanisms. Eighty-one isogenic E.
K. Alexandre, Marina Murillo-Torres, Fernando Docobo-Pérez, Álvaro Pascual, Jose Manuel Rodríguez-Martínez   +4 more
doaj   +2 more sources

In vitro antibiofilm and intracellular activity of delafloxacin against Staphylococcus aureus and Staphylococcus epidermidis in bone and joint infections [PDF]

Microbiology Spectrum
Staphylococcal bone and joint infections (BJIs) represent significant challenges for treatment. Fluoroquinolone-based combination therapies, especially involving levofloxacin, are pivotal antimicrobials in their management.
Angélique Sion, Marion Martin, Mélanie Bonhomme, Jérôme Josse, Florent Valour, Frédéric Laurent, Céline Dupieux   +6 more
doaj   +2 more sources

Genetic Mechanisms of Antimicrobial Non-Susceptibility to Novel Fluoroquinolone Delafloxacin Among Bulgarian Clinical Isolates of Streptococcus agalactiae [PDF]

Current Issues in Molecular Biology
Delafloxacin is one of the newest fluoroquinolones with a unique structure, determining better pharmacokinetic and pharmacodynamic properties, a better safety profile, and a broader spectrum of activity compared to older quinolones.
Vasil Boyanov, Alexandra Alexandrova, Raina Gergova   +2 more
doaj   +2 more sources

A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections

International Journal of Infectious Diseases, 2015
Background: A randomized, double-blind, multicenter trial was done to compare two doses of delafloxacin with tigecycline in patients with various complicated skin and skin-structure infections (wound infections following surgery, trauma, burns, or animal/
Sue Cammarata
exaly   +3 more sources